A recent study explores the potential of tirzepatide, a drug originally developed for diabetes, as an off-label treatment for weight loss in individuals without diabetes.
Tirzepatide, a GLP-1 receptor agonist, has been gaining traction for its weight loss capabilities. Traditionally prescribed for type 2 diabetes under the brand name Mounjaro, the drug is now being investigated for its effects on weight loss in non-diabetic individuals.
The study, funded by Eli Lilly and published in the journal Diabetes & Metabolism, examined data from approximately 4,100 participants with no diabetes diagnosis. The results revealed an average weight loss of 13% over six months. The majority of participants were female, with an average age of 46 and a BMI of 37.1 kg/m².
Research indicates a substantial continuation rate for tirzepatide, with 73.8% of participants using the medication for six months or longer. Dr. Emily R. Hankosky, the study’s corresponding author, highlighted the discretionary use of Mounjaro by physicians for weight management.
Related Stories
Furthermore, 32% of the study participants presented with class 3 obesity, characterized by a BMI of 40 kg/m² or higher. Over 74% encountered one or more obesity-related complications, notably dyslipidemia, hypertension, and anxiety.
Prominent figures in the medical field have shared insights on these findings. Dr. Mir Ali emphasized the alignment of results with existing research on tirzepatide’s benefits. He remarked on the challenge of distinguishing between the advantages of weight loss and the direct effects of the medication itself. Ali underscored the potential of tirzepatide in improving conditions such as high blood pressure, widely considered among the available options for effective weight loss.
Simultaneously, Dr. Jennifer Cheng emphasized the promising weight loss effects observed in non-diabetic patients. While recognizing its benefits, she highlighted the need for awareness regarding potential side effects and cost considerations. Dr. Cheng pointed out that the mechanism of action involves slowing gastric emptying, leading to reduced food intake.
Both experts advocate for additional research to explore the long-term implications of tirzepatide, particularly regarding cardiovascular and liver health. The study’s findings suggest potential applications beyond current criteria, though cost and insurance coverage remain significant factors.
The investigation into tirzepatide presents promising avenues for weight loss in non-diabetic individuals, yet further research is crucial to fully understand its long-term effects and economic feasibility.
